George Washington University has described N-ACYL fosmidomycin prodrug analogues acting as 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr; IspC) (Mycobacterium tuberculosis) and Dxr (Plasmodium falciparum) inhibitors reported to be useful for the treatment of malaria and tuberculosis.
Chemoproteomics studies have uncovered multiple potential kinase drug targets in the Plasmodium protozoan that causes malaria, and subsequent screening of approved kinase inhibitor drugs has now thrown up several hits with lethal activity at different stages of the complex life cycle of the parasite. Researchers at the University of Cape Town, South Africa, working with scientists at Glaxosmithkline plc, describe the activity in Plasmodium of one of these kinase inhibitors, the cancer drug sapanisertib, in a paper appearing in Science Translational Medicine, Oct. 19, 2022.
LONDON – The World Health Organization (WHO) is recommending the widespread rollout of Glaxosmithkline plc’s Mosquirix (RTS,S), the first malaria vaccine, following real-world evidence it is safe and can be integrated into routine immunization programs and existing malaria control measures.
An international collaborative study has identified several novel derivatives of anticancer proteasome inhibitors (PIs) that had potential as antimalarials, the authors reported in the September 28, 2021, online edition of Proceedings of the National Academy of Sciences.
The World Health Organization (WHO) and the Global Fund to Fight AIDS, Tuberculosis and Malaria signed a cooperation and financing agreement to implement 10 initiatives in 2021 through 2023 aimed at addressing persistent challenges impeding global progress against the three diseases and protecting hard-won gains from new pandemics like COVID-19.
